A biotechnology company aiming to curb the large-scale use of antibiotics in livestock production has secured fresh capital. Nutrivert, which is developing a novel non-antibiotic growth promotant, announced it has closed a $2.4M Series A funding round.
The investment will accelerate Nutrivert's mission to provide a safe and effective alternative to traditional antibiotics in animal agriculture. Its technology seeks to address growing concerns over antibiotic resistance by offering a sustainable solution for promoting animal growth without relying on conventional antimicrobial agents.















